AAG
BTAI icon

Armstrong Advisory Group’s BioXcel Therapeutics BTAI Stock Holding History

Armstrong Advisory Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-63
Closed -$2.95K – 796
2024
Q1 		$2.95K Hold
63
– – ﹤0.01% 689
2023
Q4 		$2.95K Hold
63
– – ﹤0.01% 689
2023
Q3 		$2.53K Sell
63
-12
-16% -$1.21K ﹤0.01% 763
2023
Q2 		$7.99K Buy
75
+12
+19% +$4K ﹤0.01% 611
2023
Q1 		$18.7K Hold
63
– – ﹤0.01% 486
2022
Q4 		$21.5K Buy
+63
New +$15.2K ﹤0.01% 476

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Armstrong Advisory Group's BTAI Position: Q2 2024 in Review

Armstrong Advisory Group sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 63 shares — an estimated $2.95K sold.

Armstrong Advisory Group first reported a position in BTAI in Q4 2022 and held it in 6 quarters. The position peaked at $21.5K in Q4 2022. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Armstrong Advisory Group reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Armstrong Advisory Group sold 63 BioXcel Therapeutics shares in Q2 2024, an estimated $2.95K.
  • Armstrong Advisory Group first reported a position in BioXcel Therapeutics in Q4 2022 and held it in 6 quarters.
  • Armstrong Advisory Group's BioXcel Therapeutics position peaked at $21.5K in Q4 2022.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Armstrong Advisory Group's 13F filing for Q2 2024, filed 12 Jul 2024.